Lupin Limited (NSE: LUPIN) stock price drops 5% intraday to ₹2239.0, breaking below key support level in the Healthcare sector.
Lupin Limited's Q1 FY27 investor presentation highlights strategic growth, key financial metrics, and significant developments.
Lupin Limited (NSE: LUPIN) receives U.S. FDA approval for Diazepam Injection USP, expanding its therapeutic offerings.
Lupin Limited (LUPIN) announces U.S. FDA approval and launch of Sugammadex Injection, a bioequivalent to Bridion®.
Lupin Limited (NSE: LUPIN) has been recognized among India’s Best Employers in the Nation Builders Category by Great Place To Work® India for 2026.
Lupin Limited, NSE: LUPIN, recognized as one of the world’s most sustainable companies in 2026 by TIME and Statista.
Lupin Limited (LUPIN) secures EMA approval for expanded pediatric indication for NaMuscla®, broadening access to treatment for non-dystrophic myotonic disord.
